Company & Sponsor Intelligence
Teva Neuroscience, Inc.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed4
Countries0
Therapeutic footprint
multiple_sclerosis
Indexed studies
NCT00238654A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
multiple_sclerosis · COMPLETED
multiple_sclerosis · COMPLETED
NCT00240006A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
multiple_sclerosis · PHASE4
multiple_sclerosis · PHASE4
NCT01167426Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
multiple_sclerosis · PHASE3
multiple_sclerosis · PHASE3
NCT00220922A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
multiple_sclerosis · PHASE4
multiple_sclerosis · PHASE4
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →